The Phase III trial tested Lilly's once-weekly triple receptor agonist for efficacy and safety in people with obesity and type 2 diabetes.
Recap by typeshit. Full story at Medical Xpress on MSN.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
A Minutes of Health clip, in English and Arabic, walks through what the GLP-1 hormone does and how popular treatments use it.
In 4,554 matched patients with type 2 diabetes and CKD, GLP-1/GIP drugs were tied to a 29% lower relative hazard of kidney decline than finerenone over 2.5 years.
Loading…